GI Dynamics opens Australian IPO; Intersect ENT gets FDA OK for PMA;

> GI Dynamics has opened the offering period on its Australian IPO. It will issue more than 72 million shares at A$1.10 per CDI or A$5.50 per share. Item

> The FDA has approved Intersect ENT's PMA application for the Propel mometasone furoate implant offering localized, controlled drug delivery for chronic sinusitis patients. Intersect ENT release

> Microvisk Technologies has introduced its handheld devices to monitor the blood clotting status of patients in the U.S. The devices have attracted interest from distributors and potential partners ahead of clinical trials this fall and product launches in 2012. Microvisk release

> GE Healthcare has reached a settlement with Bio-Rad Laboratories in an IP lawsuit related to GE Healthcare Life Sciences' technology for studying molecular interactions with Surface Plasmon Resonance. GE Healthcare

> The Justice Department is looking into whether Pfizer may have bribed overseas officials. But it is not the only firm to be investigated over potential issues. Earlier this year, Johnson & Johnson agreed to pay almost $80 million to resolve bribery allegations in Europe and indications that it had paid kickbacks to Iraqi officials during the regime of Saddam Hussein. Those allegations involved the sale of medical devices. News

> TearScience has appointed Diethart Reichardt as senior VP of the European region, which includes Europe, Middle East and Africa. TearScience release

And Finally... Washington University School of Medicine researchers have developed a new technique that provides rapid access to brain landmarks formerly only available at autopsy. Report